NCT07044544View on ClinicalTrials.gov

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Myeloid MalignancyHematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

G-CSF

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.

DRUG

Decitabine

Decitabine is a hypomethylating agent.

DRUG

Venetoclax

Venetoclax is a selective inhibitor of BCL-2 protein.

Trial Locations (1)

35294

University of Alabama at Birmingham, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER